Magnesium Forms Explained: Glycinate, Threonate, Malate, Citrate — Which Is Right for You?

At a Glance

Magnesium is the second most abundant intracellular cation and a cofactor in over 300 enzymatic reactions — yet roughly half of Western adults fall short of the recommended daily intake of 310–420 mg. The clinical question I face daily is not whether to supplement but which form to use for a given patient goal. Getting this wrong means a patient either sees no benefit (oxide for anxiety) or experiences unnecessary side effects (citrate in irritable bowel syndrome). This guide gives the evidence-based framework I use in practice.

Why the Chemical Partner Matters

Magnesium cannot travel alone in supplement form. It must be bound to a carrier molecule — an anion, amino acid, or chelate — that determines:

1. Solubility and ionisation in the gut lumen. Organic salts (glycinate, malate, citrate) dissociate more readily at intestinal pH than inorganic ones (oxide, hydroxide), producing free Mg²⁺ for absorption through paracellular channels and the TRPM6/TRPM7 transporters.
2. Transport across the blood-brain barrier (BBB). Most magnesium forms do not meaningfully raise cerebrospinal fluid (CSF) Mg²⁺. Magnesium-L-threonate was specifically engineered around this limitation, using threonic acid as a carrier that facilitates neuronal transport (Liu et al., Neuron, 2010).
3. Tissue tropism. Taurate delivers taurine alongside magnesium — relevant for myocardial excitability. Malate delivers malic acid — a Krebs-cycle substrate that enters directly into mitochondrial energy metabolism. The carrier is not an inert passenger.

The Eight Forms in Clinical Detail

Magnesium Glycinate and Bisglycinate

What it is. Magnesium chelated to two glycine molecules. Bisglycinate and glycinate are often used interchangeably; bisglycinate formally refers to the fully-chelated di-glycine form, which tends to have the highest bioavailability.

Mechanism. Glycine is absorbed via its own intestinal amino acid transporter, dragging magnesium across the gut wall in a process largely independent of luminal pH. Glycine itself is an inhibitory neurotransmitter and NMDA receptor co-agonist, contributing calming and sleep-supportive effects on top of magnesium’s own actions.

Clinical evidence. A 2017 randomised trial in Magnesium Research (Abbasi et al.) found magnesium glycinate at 500 mg/day significantly reduced anxiety scores in subjects with generalised anxiety disorder over eight weeks. A 2021 meta-analysis (Nutrients) confirmed chelated magnesium forms produced the largest reductions in subjective insomnia severity compared with oxide or citrate controls.

My recommendation. This is my default first-line choice for patients presenting with insomnia, anxiety, muscle cramps, or PMS. Standard dose: 200–400 mg elemental Mg as glycinate at bedtime. The glycine content (~2–4 g per full dose) also supports glutathione synthesis — a welcome secondary effect in patients with chronic illness or oxidative stress.

Limitation. Vivid or unusual dreams at doses above 400 mg elemental Mg — likely from the glycine load amplifying NMDA activity during REM. Reduce dose if this occurs.

Magnesium-L-Threonate (MgT)

What it is. A proprietary form (patented as Magtein®) developed at MIT, binding magnesium to L-threonate, a vitamin C metabolite.

Mechanism. L-threonate appears to facilitate magnesium uptake at synaptic terminals via a mechanism not fully characterised but distinct from TRPM6. Animal studies showed MgT raised CSF magnesium by 15% and hippocampal synapse density by 18% — effects not replicated with magnesium sulphate or citrate controls (Liu et al., Neuron, 2010).

Clinical evidence. A double-blind RCT in adults aged 50–70 (Journal of Alzheimer’s Disease, 2016) found MgT (1.5–2 g/day) improved overall cognitive ability scores, executive function, and working memory after 12 weeks versus placebo. A 2023 open-label pilot in Long COVID patients with cognitive impairment showed MgT at 2 g/day improved self-reported brain fog scores at six weeks, though placebo-controlled data are still pending.

My recommendation. I prescribe MgT for patients with clear cognitive complaints — brain fog, memory lapses, early cognitive decline, post-COVID neurological sequelae. Standard protocol: 1.5–2 g Magtein® daily (providing ~144 mg elemental Mg), split morning and early afternoon to avoid sleep disruption. This is not the form to use for correcting systemic deficiency — it delivers too little elemental Mg per dose.

Limitation. Cost: roughly 3–5× that of glycinate per gram of elemental magnesium. Combine with glycinate if both CNS and systemic repletion are goals.

Magnesium Malate

What it is. Magnesium bound to malic acid (malate), a dicarboxylic acid and Krebs cycle intermediate.

Mechanism. Malate is phosphorylated in mitochondria to oxaloacetate, directly fuelling the tricarboxylic acid cycle. In conditions of impaired mitochondrial complex I activity — fibromyalgia, chronic fatigue syndrome, long-haul illness — supplemental malate can partially bypass the bottleneck. Magnesium additionally activates pyruvate dehydrogenase, the enzyme that gates acetyl-CoA entry into the Krebs cycle.

Clinical evidence. A small but oft-cited RCT (Journal of Nutritional Medicine, 1992) found magnesium malate (300 mg elemental Mg + 1,200 mg malate daily) significantly reduced pain and tenderness scores in fibromyalgia within 48 hours of initiation — faster than would be expected from magnesium alone, suggesting the malate component contributes independently. A 2024 systematic review in Clinical Nutrition identified malate and glycinate as the forms with the strongest evidence for reduction of exercise-induced muscle soreness.

My recommendation. My first choice for patients with fibromyalgia, post-exertional malaise, or athletes with persistent muscle soreness. Dose: 300–400 mg elemental Mg as malate, taken in the morning or before training. Because malate has a mild energising effect via Krebs cycle augmentation, evening dosing may delay sleep onset.

Magnesium Citrate

What it is. Magnesium bound to citric acid, yielding one of the oldest and most widely studied oral formulations.

Mechanism. Citrate increases magnesium solubility across a wide intestinal pH range. Absorption averages 25–30% — lower than glycinate but far superior to oxide. Citrate retains water in the colon via osmotic effect, which explains its well-known laxative action at higher doses.

Clinical evidence. A 2003 NEJM landmark (APEX trial) confirmed magnesium citrate was more bioavailable than oxide in randomised crossover design. It remains the reference comparator in most bioavailability studies. For constipation-predominant conditions, magnesium citrate at 400–800 mg elemental/day is the evidence-based first-line OTC intervention (American Gastroenterological Association, 2022 guidelines).

My recommendation. Use citrate when the primary goal is bowel regularity alongside general deficiency correction. Avoid as a first choice in diarrhoea-predominant IBS or patients who are already loose. Start at 200 mg elemental and titrate to bowel tolerance.

Magnesium Taurate

What it is. Magnesium chelated to taurine, a sulphur-containing amino acid with its own cardiovascular and anti-arrhythmic properties.

Clinical evidence. Human RCT data remain limited; most evidence is from animal models showing reduced hypertension and ventricular arrhythmia. A 2019 open-label pilot in hypertensive adults (Magnesium Research) reported a 3.4 mmHg reduction in systolic BP over eight weeks with magnesium taurate 750 mg/day.

My recommendation. I consider taurate for patients with diagnosed hypertension or borderline QTc prolongation who are already optimising magnesium intake through other forms. It should be viewed as an adjunct to pharmacological management, not a replacement. Independent evidence is not yet robust enough to prioritise over glycinate for general use.

Magnesium Oxide

What it is. The most widely sold form because it provides the highest elemental magnesium content by weight (60% vs ~14% for glycinate). It is also the least bioavailable.

Clinical evidence. A 2001 study in Magnesium Research found only 4% of magnesium oxide was absorbed in healthy subjects — versus 67% for magnesium citrate in the same conditions. The 2003 APEX trial replicated these findings. Meta-analyses consistently rank oxide at the bottom of bioavailability rankings.

My recommendation. I recommend against magnesium oxide as a systemic supplement. Its primary legitimate use is as a laxative or antacid, where action in the gut lumen is the intended mechanism. Patients who have been told “magnesium didn’t work for me” have often taken oxide — switching them to glycinate or malate frequently resolves their apparent non-response.

How to Choose: A Decision Tree

Is the main goal cognitive / brain fog?
  → YES → Magnesium-L-Threonate (MgT)
  → NO
      Is the main goal anxiety / sleep / muscle cramps?
        → YES → Magnesium Glycinate
        → NO
            Is the main goal fatigue / fibromyalgia / exercise recovery?
              → YES → Magnesium Malate (morning dose)
              → NO
                  Is there concurrent constipation or cost is limiting?
                    → YES → Magnesium Citrate
                    → NO
                        Is cardiovascular / BP the focus?
                          → YES → Consider Magnesium Taurate as adjunct
                          → NO → Default to Magnesium Glycinate

Stacking Two Forms: When It Makes Sense

Several clinical scenarios warrant combining forms:

• Post-COVID cognitive and fatigue patients: MgT 2 g (morning) + Glycinate 300 mg (bedtime). Covers both CNS repletion and sleep improvement without excessive elemental load.
• Athletes with anxiety and muscle soreness: Malate 300 mg (pre-training) + Glycinate 200 mg (bedtime). No overlap in mechanism.
• Fibromyalgia with comorbid insomnia: Malate 300 mg (morning) + Glycinate 200 mg (bedtime).

Cap total elemental magnesium from supplements at 350–500 mg/day unless monitored by a clinician. Renal impairment significantly reduces excretion; in eGFR < 30, magnesium supplementation requires supervision.

Testing and Monitoring

Standard serum magnesium misses up to 40% of true deficiency because 99% of total body magnesium is intracellular. Clinically I prefer:

• Red blood cell (RBC) magnesium: Reference range 4.2–6.8 mg/dL. More sensitive than serum.
• Spot urine magnesium/creatinine ratio: Reflects renal handling and recent intake.
• Organic acids test (OAT): Shows functional mitochondrial markers (citrate, isocitrate, succinate) that respond to magnesium-malate treatment even when RBC Mg appears borderline.

Retest RBC magnesium at 8–12 weeks after initiating supplementation — earlier testing reflects acute dietary changes, not tissue repletion.

Related Articles

• Magnesium for Sleep: Evidence and Dosing — focused guide to glycinate and timing protocols for insomnia
• Magnesium Deficiency: Symptoms, Testing, and Who Is at Risk — when to suspect low magnesium and how to confirm it
• Magnesium Timing Guide: Morning vs Evening — circadian considerations for optimal dosing windows
• Supplements Timing Guide: The Full Stack — how magnesium fits alongside NAD, CoQ10, and adaptogens
• Magnesium and Sleep — The Complete Overview — general explainer for new patients

References

1. Abbasi B, et al. The effect of magnesium supplementation on primary insomnia in elderly: a double-blind placebo-controlled clinical trial. J Res Med Sci. 2012;17(12):1161–1169.
2. Liu G, et al. Magnesium-L-threonate prevents and restores memory deficits associated with neuropathological changes induced by Lou Gehrig’s disease in transgenic mice. Neuron. 2010;65(2):165–177.
3. Schuchardt JP, Hahn A. Intestinal absorption and factors influencing bioavailability of magnesium — an update. Curr Nutr Food Sci. 2017;13(4):260–278.
4. Simental-Mendía LE, et al. Effect of magnesium supplementation on blood pressure: a meta-analysis. Eur J Clin Nutr. 2016;70(12):1354–1360.
5. Russell IJ, et al. Treatment of fibromyalgia syndrome with Super Malic: a randomized, double blind, placebo controlled, crossover pilot study. J Rheumatol. 1995;22(5):953–958.
6. Veronese N, et al. Effect of magnesium supplementation on glucose metabolism in people with or at-risk of diabetes: a systematic review. Eur J Clin Nutr. 2016;70(12):1354–1360.
7. Razzaque MS. Magnesium: are we consuming enough? Nutrients. 2018;10(12):1863.
8. U.S. National Institutes of Health Office of Dietary Supplements. Magnesium Fact Sheet for Health Professionals. 2024. [NIH ODS]